0001179110-18-002591.txt : 20180222
0001179110-18-002591.hdr.sgml : 20180222
20180222162538
ACCESSION NUMBER: 0001179110-18-002591
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180220
FILED AS OF DATE: 20180222
DATE AS OF CHANGE: 20180222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WALSH MATTHEW M
CENTRAL INDEX KEY: 0001269428
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36867
FILM NUMBER: 18632890
MAIL ADDRESS:
STREET 1: ALLERGAN
STREET 2: 5 GIRALDA FARMS
CITY: MADISON
STATE: NJ
ZIP: 07940
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allergan plc
CENTRAL INDEX KEY: 0001578845
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
BUSINESS PHONE: (216) 523-5000
MAIL ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis plc
DATE OF NAME CHANGE: 20130930
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis Ltd
DATE OF NAME CHANGE: 20130607
4
1
edgar.xml
FORM 4 -
X0306
4
2018-02-20
0
0001578845
Allergan plc
AGN
0001269428
WALSH MATTHEW M
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
DUBLIN
L2
D17 E400
IRELAND
0
1
0
0
EVP, Chief Financial Officer
Ordinary Shares, par value $0.0001
2018-02-20
4
A
0
13076
160.59
A
13076
D
Ordinary Shares, par value $0.0001
2018-02-20
4
A
0
9340
160.59
A
22416
D
Ordinary Shares, par value $0.0001
2018-02-21
4
P
0
2000
160.94
A
24416
D
Performance-Based Restricted Stock Unit
2018-02-20
4
A
0
28021
0
A
Ordinary Shares
28021
28021
D
The reported securities are restricted share units ("RSUs"), each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 25% on each of February 20, 2019, February 20, 2020, February 20, 2021 and February 20, 2022.
Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
The reported securities are RSUs, each of which represents a right to receive one ordinary share of Allergan plc. The RSUs were issued pursuant to the provisions of the 2013 Incentive Award Plan of Allergan plc and shall vest 20% on each of February 20, 2019, February 20, 2020, February 20, 2021, February 20, 2022 and February 20, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.80 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Represents performance-based restricted share units ("PSUs") which will vest as to 50% of the total grant on each of December 31, 2020 and December 31, 2021, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of ordinary shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.
/s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person
2018-02-22